First Department of Surgery, Shiga University of Medical Science, Seta-tsukinowa-cho, Otsu, Shiga, 520-2192, Japan.
Int J Clin Oncol. 2012 Jun;17(3):240-9. doi: 10.1007/s10147-011-0281-8. Epub 2011 Jul 20.
Prediction of poor patient outcome as a effect of adjuvant therapy in stage II colorectal cancer (CRC) remains a matter of controversy. Tumor expression of CD10 and CD15 is reportedly related to poor outcome in CRC. In this study, we investigated whether the expression of CD10 and CD15 is a predictor of outcome and the effect of adjuvant therapy in stage II CRC.
Immunohistochemical analyses for CD10 and CD15 and some additional markers (CD11b, CD14, CD163, CD3, and CD20) were performed using paraffin sections of CRC specimens from 57 patients who had undergone curative surgical treatments between 1998 and 2004. Forty of these patients received postoperative adjuvant therapy. We distinguished between expression in tumor cells (tCD10 and tCD15), in stromal cells (sCD10), and infiltrating immune cells (iCD10 and iCD15).
Expression of iCD10 was observed in 21.1% (12/57) of the specimens examined. Of all expression patterns, only iCD10 expression at the cancer invasion front was a useful predictor of a disease-free period and overall survival in stage II CRC. Adjuvant therapy improved the outcome of iCD10(+) patients. CD10(+) immune cells were heterogeneous in origin and partially overlapped the cells positive for myeloid lineage markers, including CD11b and CD15.
iCD10 expression at the tumor invasion front is a useful marker for predicting a high risk of recurrence and mortality in stage II CRCs. CD10(+) immune cells appear to be of myeloid origin.
辅助治疗对 II 期结直肠癌（CRC）患者预后不良的预测仍然存在争议。肿瘤 CD10 和 CD15 的表达与 CRC 预后不良有关。在这项研究中，我们研究了 CD10 和 CD15 的表达是否是 II 期 CRC 患者预后和辅助治疗效果的预测因子。
使用免疫组织化学分析方法检测 57 例 1998 年至 2004 年期间接受根治性手术治疗的 CRC 标本中的 CD10 和 CD15 及其他一些标志物（CD11b、CD14、CD163、CD3 和 CD20）的表达。其中 40 例患者接受了术后辅助治疗。我们区分了肿瘤细胞（tCD10 和 tCD15）、基质细胞（sCD10）和浸润免疫细胞（iCD10 和 iCD15）的表达。
在 57 例标本中，21.1%（12/57）观察到 iCD10 的表达。在所有的表达模式中，只有肿瘤侵袭前沿的 iCD10 表达是 II 期 CRC 无病生存期和总生存期的有用预测因子。辅助治疗改善了 iCD10（+）患者的预后。CD10（+）免疫细胞起源具有异质性，部分与髓系标志物（包括 CD11b 和 CD15）阳性的细胞重叠。
肿瘤侵袭前沿的 iCD10 表达是预测 II 期 CRC 复发和死亡高风险的有用标志物。CD10（+）免疫细胞似乎来自髓系。
